UPDATE : Tuesday, August 14, 2018
상단여백
Huons Global posts ￦93.2 billion in Q2 sales
Huons Global said Tuesday the company and its subsidiaries recorded 93.2 bi...
by Lee Han-soo  |  2018-08-14 15:22
라인
Psoriasis drug Tremfya may add indication for Crohn’s disease
Janssen Korea has obtained approval for clinical trials on plaque psoriasis...
by Lee Hye-seon  |  2018-08-14 12:07
라인
US court to proceed with Pfizer’s lawsuit against J&J
A U.S. district court has denied Johnson & Johnson’s (J&J) motion to dismis...
by Lee Han-soo  |  2018-08-14 10:51
라인
Parkinson’s drug Azilect beats market leader Stalevo
A rising star drug in the Parkinson’s disease treatment market defeated the...
by So Jae-hyeon  |  2018-08-13 15:32
라인
13 gadolinium contrast agents banned until year-end
The government said it would ban 13 linear gadolinium contrast agents used ...
by Lee Hye-seon  |  2018-08-13 14:36
라인
Huons to conduct clinical trials for BTX for eye wrinkles
Huons Global said Monday that it has received approval from the Ministry of...
by Lee Han-soo  |  2018-08-13 14:21
라인
[News Focus] Valsartan chaos reveals Korean drugmakers’ weakness
The pharmaceutical industry is having time for self-reflection, admitting t...
by So Jae-hyeon  |  2018-08-13 14:21
라인
Janssen Korea to observe 120 for post-marketing survey of ulcerative colitis treatment
The number of cases for additional indications of ulcerative colitis after ...
by Lee Hye-seon  |  2018-08-10 18:25
라인
Pfizer Vitals suffers double-whammy from poor performance, valsartan recall
Pfizer Vitals, which claimed to stand for quality generics, has suffered a ...
by So Jae-hyun  |  2018-08-10 17:56
라인
Cannabinoid group uses blockchain to conduct clinical trials on CBD
Kwon Yong-hyun (second from left), president of the Korean Cannabinoid Asso...
by Lee Han-soo  |  2018-08-10 14:53
라인
Daewoong, Chong Kun Dang compete to develop dementia treatments
The rivalry between Daewoong Pharmaceutical and Chong Kun Dang is getting i...
by So Jae-hyun  |  2018-08-09 15:55
라인
JW to launch drug combining Livaro, Ezetimibe
JW Pharmaceuticals has begun to develop a drug which combines two dyslipide...
by Lee Hye-seon  |  2018-08-09 11:59
라인
Competition heats up among Korean Botox makers to develop ‘kDa’
As the global expansion of domestic botulinum toxin (BTX) products is becom...
by So Jae-hyeon  |  2018-08-08 16:53
라인
GSK publishes SWORD data on 2-drug HIV regimen
ViiV Healthcare, the HIV specialty firm of GlaxoSmithKline, presented 100-w...
by Marian Chu  |  2018-08-08 14:42
라인
Takeda gets approval for antihypertension drug Edarbyclor
Takeda Pharmaceutical Korea said Tuesday it got approval for its antihypert...
by Marian Chu  |  2018-08-07 17:24
라인
Bukwang registers patients for P2 clinical trial of diabetes treatment
Bukwang Pharmaceutical said Tuesday that it has finished enrolling patients...
by Lee Han-soo  |  2018-08-07 17:24
라인
Over 36.8 billion won worth of banned valsartan-based drugs sold last year
More than 36.9 billion won worth of banned antihypertensive drugs were pres...
by So Jae-hyeon  |  2018-08-07 15:40
라인
59 Korea-made high blood pressure medications called back over cancer fears
Locally produced antihypertensive medication containing the active ingredie...
by Marian Chu  |  2018-08-06 17:50
라인
Chong Kun Dang gets license for generic immunosuppressant
Chong Kun Dang said it has obtained approval for Raparobell, a generic copy...
by So Jae-hyeon  |  2018-08-03 15:38
라인
GC Labcell, AbClon to develop CAR-NK cell treatment
GC Labcell CEO Park Dae-woo (left) and AbClon CEO Lee Jong-seo signed a coo...
by Lee Han-soo  |  2018-08-03 14:40
-12345678910-
Local patents increasingly target obesityLocal patents increasingly target obesity
여백
Most viewed
여백
Opinion
[Column] Buy expensive and waste your money?
[Column] Buy expensive and waste your money?
[Reporter’s Notebook] Korean medical workers living in fear of violence
[Reporter’s Notebook] Korean medical workers living in fear of violence
[Column] Carcinogen threat will continue unless Seoul overhauls generics approval system
[Column] Carcinogen threat will continue unless Seoul overhauls generics approval system
여백
Back to Top